Skip to content
Search AI Powered

Latest Stories

India's Serum Institute expects WHO emergency approval for AstraZeneca vaccine soon

THE Serum Institute of India (SII) expects WHO emergency use authorization soon for the Oxford University/AstraZeneca coronavirus vaccine, which it is producing for mid and low income countries, its chief executive said.

The World Health Organization (WHO) listed Pfizer and BioNTech's Covid-19 shot for emergency use on December 31 as it sought to accelerate vaccination in the developing world, which is badly lagging western countries.


"The emergency use license from the WHO should be available and coming through in the next week or two, hopefully, because we have submitted everything," Adar Poonawalla said.

Poonawalla said SII, the world's biggest vaccine maker, was trying to begin supplies to the WHO-backed COVAX initiative by the end of January. It is selling each dose at $3 for low-income countries and at a "slightly higher" price for others.

Some 189 countries have joined the programme, which was established to ensure equitable distribution of vaccines.

From sending about 20 million doses for the initiative in February, SII will raise this to 50 million per month from around April, while simultaneously selling 30-40 million doses each month to India, Poonawalla added.

SII has already sold 11 million doses to the government, which is due to begin a mass vaccination campaign on Saturday(16).

Poonawalla said SII would start stockpiling "upwards of 40-50 million doses per month" of the Novavax coronavirus vaccine candidate from around April.

He said his family owned company, which was founded by his father Cyrus Poonawalla in 1966, is well placed to distribute 1 billion doses of vaccines this year, with COVAX having an option to buy 450 million each of the AstraZeneca and Novavax vaccines.

Apart from Brazil and Bangladesh, which are expected to soon get supplies of the AstraZeneca shot from SII, Poonawalla said the Pune-based firm has also been approached by Morocco, South Africa and Saudi Arabia.

As demand for vaccines booms, a so-called special purpose vehicle housing SII's pandemic-related products should now be valued at $12 billion to $13 billion, SII's CEO added.

"We are in a unique position to be able to make so many different vaccines at a huge volume and capacity. For an investor to come in at a $12-13 billion valuation, it will be a fantastic deal, leaving a lot of upside."

More For You

Unlocking ancient healing: The power and precision of Vedic mantras

Divya Chikitsa Mantras use sound and vibrations to produce profound healing and transformational effects

Unlocking ancient healing: The power and precision of Vedic mantras

Ashwini Guruji

You may have heard of Sanjeevani Vidya, bestowed by Guru Shukracharya, which could revive the dead, or the Sanjeevani Buti that restored Lakshman’s life. Tales like Madhu Vidya, enabling immortality, and the Ashvini Kumars’ Chyawanprasha, rejuvenating Sage Chyawan, are not mere stories but the practical achievements of Vedic rishis. Masters of Creation, they understood the human body as a microcosm of the universe. The proof of these ancient sciences lies in modern scientific discoveries, many rooted in Vedic shastras. Visit www.dhyanfoundation.com to explore this connection.

Though much of this ancient knowledge has been lost in Kaliyuga and many herbs have become extinct, fragments remain accessible and potent. Divya Chikitsa Mantras from Sanatan Kriya are one such gem. These mantras use sound and vibrations to produce profound healing and transformational effects. Comprising seven mantras, they unclog energy channels (nadis), activate specific centers, and channel divine energies into the practitioner.

Keep ReadingShow less
nhs-hospital-getty

NHS faces pressure as flu admissions rise sharply

FLU cases in the country have surged, with over 5,000 hospital admissions last week, marking a sharp increase as the NHS faces pressure from a winter quad-demic of flu, Covid, respiratory syncytial virus (RSV), and norovirus.

According to The Times, flu admissions rose from 4,102 on Christmas Day to 5,074 by 29 December.

Keep ReadingShow less
AI-diabetes-risk-tool-iStock

World's first AI diabetes risk tool to be tested by NHS in 2025

THE NHS in England is set to launch a world-first trial of an artificial intelligence (AI) tool that predicts the risk of developing type 2 diabetes up to 13 years before symptoms appear.

The trial, scheduled for 2025, will take place at Imperial College Healthcare NHS Trust and Chelsea and Westminster Hospital NHS Foundation Trust, The Guardian reported.

Keep ReadingShow less
Agni: The sacred science of fire and its transformative power

Fire (agni) holds a profound significance in Vedic rituals

iStock

Agni: The sacred science of fire and its transformative power

Ashwini Guruji

Agni, the first word of the Rig Veda, holds a profound significance. It is, in fact, a wondrous element. While most are familiar with fire for its heat and light, very few understand that fire sustains our body and plays a pivotal role in cleansing it and the surrounding elements. Even fewer appreciate its role as a medium to connect with the Devlok (realm of the divine), and hardly anyone explores its potential to manifest changes within and around them. Dhyan Ashram is one such rare place in today’s world where sadhaks (practitioners) experiment with and experience the extraordinary properties of fire.

In Vedic times, yagyas were a routine practice. They were not mere rituals but a precise science designed to invoke and channel the forces of Creation through the medium of fire. The Vedic Shastras detail nearly 400 types of yagyas, each with a specific purpose.

Keep ReadingShow less
genomics-iStock

A recent RHO review highlighted significant gaps in health equity data for genomic services. (Representational image: iStock)

NHS study to tackle inequalities in access to genomic medicine

THE NHS Race and Health Observatory (RHO) and NHS England have launched an 18-month research project to address disparities faced by ethnic minority groups in accessing genomic medicine.

The initiative will examine racial and ethnic biases in the NHS Genomic Medicine Service (GMS) through national and regional assessments of health inequalities.

Keep ReadingShow less